Carterra technology will allow Ordaōs to accelerate its mission of leveraging advanced technologies to efficiently and effectively design novel life-changing therapies for patients in need.
Ordaōs, a human-enabled, machine-driven drug design company that creates novel and customized mini-proteins, announced it has acquired an LSA platform from Carterra, a leading provider of high-throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates, particularly in AI/ML workflows. The implementation of this technology will enhance Ordaōs’ capabilities to rapidly design innovative new drug candidates across therapeutic areas, particularly for difficult-to-treat diseases.
The Carterra LSA platform offers best-in-class throughput and speed, minute sample usage, and the ability to analyze up to 150,000 interactions in a single assay. The LSA is also the only platform that enables true AI/ML approaches to protein design and characterization helping scientists to speed and optimize drug discovery workflows.
“At Ordaōs, our mission is to create novel and customized mini-proteins that will help our pharma and biotech partners develop safer and more-effective life-saving treatments for patients in need,” said David Longo, CEO of Ordaōs. “We are thrilled to bring the Carterra LSA platform into our drug design process with its high-throughput technology that will further propel our efforts for delivering more value to our partners.”
Ordaōs’ proprietary Design Engine leverages multitask, meta-learning to create novel mini-proteins from scratch. Mini-proteins are a new class of proteins that have the potential to revolutionize biologics in medicine. Mini-proteins have several potential advantages over larger alternatives, including better penetrability, stability, solubility, and lower costs. The Carterra LSA will help fuel Ordaōs’ efforts to enhance its technological capabilities by providing speed and efficiencies to critical laboratory processes.
“We couldn’t be more excited about the growing relationship with Ordaōs,” said Tim Germann, Chief Commercial Officer at Carterra. “Machine-driven drug design is not the future, it’s now because of enabling AI/ML technologies like the LSA.”
SOURCE: PRNewswire